𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma

✍ Scribed by Marco Colleoni; Roberto Buzzoni; Emilio Bajetta; A. Maria Bochicchio; Cesare Bartoli; Riccardo Audisio; Giuliano Bonfanti; Franco Nolè

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
662 KB
Volume
72
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 study of erlotinib in patients w
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
✍ Melanie B. Thomas; Romil Chadha; Katrina Glover; Xuemei Wang; Jeffrey Morris; Th 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views

## Abstract ## BACKGROUND. Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR. The primary objective of this study was to determine the proporti

A randomized multicenter phase II clinic
A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma
✍ Qinghua Zhou; Xun Sun; Lingyuan Zeng; Jie Liu; Zhirong Zhang 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 151 KB

## From the clinical editor: Intravenous administration of mitoxantrone-loaded polybutylcyanacrylate nanoparticles (dhad-pbca-nps) allows increased cytotoxicity in hepatic tumors and prolonged the median survival periods to 5.46 months compared to 3.23 months in controls.